These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 31129911)

  • 41. Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study.
    Janssens GN; van Leeuwen MAH; van der Hoeven NW; de Waard GA; Nijveldt R; Diletti R; Zijlstra F; von Birgelen C; Escaned J; Valgimigli M; van Royen N
    J Cardiovasc Transl Res; 2016 Jun; 9(3):249-256. PubMed ID: 27102290
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Periprocedural platelet inhibition with cangrelor in P2Y
    Droppa M; Spahn P; Takhgiriev K; Müller KAL; Alboji A; Straub A; Rath D; Jeong YH; Gawaz M; Geisler T
    Int J Cardiol; 2016 Nov; 223():848-851. PubMed ID: 27580219
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial.
    D'Amario D; Restivo A; Leone AM; Vergallo R; Migliaro S; Canonico F; Galli M; Trani C; Burzotta F; Aurigemma C; Niccoli G; Buffon A; Montone RA; Flex A; Franceschi F; Tinelli G; Limbruno U; Francese F; Ceccarelli I; Borovac JA; Porto I; Crea F
    Trials; 2020 Feb; 21(1):192. PubMed ID: 32066489
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction).
    Pu J; Ding S; Ge H; Han Y; Guo J; Lin R; Su X; Zhang H; Chen L; He B;
    Circulation; 2017 Oct; 136(16):1462-1473. PubMed ID: 28844990
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardioprotective Effects of Intracoronary Morphine in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Prospective, Randomized Trial.
    Gwag HB; Kim EK; Park TK; Lee JM; Yang JH; Song YB; Choi JH; Choi SH; Lee SH; Chang SA; Park SJ; Lee SC; Park SW; Jang WJ; Lee M; Chun WJ; Oh JH; Park YH; Choe YH; Gwon HC; Hahn JY
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28373244
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA
    JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study.
    Montalescot G; Lassen JF; Hamm CW; Lapostolle F; Silvain J; ten Berg JM; Cantor WJ; Goodman SG; Licour M; Tsatsaris A; van't Hof AW
    Am Heart J; 2013 Apr; 165(4):515-22. PubMed ID: 23537967
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts.
    Barrabés JA; Inserte J; Mirabet M; Quiroga A; Hernando V; Figueras J; Garcia-Dorado D
    Thromb Haemost; 2010 Jul; 104(1):128-35. PubMed ID: 20431845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of prasugrel versus ticagrelor on coronary microcirculation in patients undergoing pharmacoinvasive strategy - acute and short-term results.
    Agrawal RS; Yusuf J; Mahajan B; Mehta V; Mandal S; Mukhopadhyay S
    Coron Artery Dis; 2023 Sep; 34(6):381-388. PubMed ID: 37471285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gradual Versus Abrupt Reperfusion During Primary Percutaneous Coronary Interventions in ST-Segment-Elevation Myocardial Infarction (GUARD).
    Sezer M; Escaned J; Broyd CJ; Umman B; Bugra Z; Ozcan I; Sonsoz MR; Ozcan A; Atici A; Aslanger E; Sezer ZI; Davies JE; van Royen N; Umman S
    J Am Heart Assoc; 2022 May; 11(10):e024172. PubMed ID: 35574948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
    Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL
    JAMA Cardiol; 2017 Feb; 2(2):127-135. PubMed ID: 27902833
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Feasibility and safety of cangrelor in patients with suboptimal P2Y
    Selvarajah A; Tavenier AH; Bor WL; Houben V; Rasoul S; Kaplan E; Teeuwen K; Hofma SH; Lipsic E; Amoroso G; van Leeuwen MAH; Berg JMT; van 't Hof AWJ; Hermanides RS
    BMC Cardiovasc Disord; 2021 Jun; 21(1):292. PubMed ID: 34118880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
    Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
    Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis.
    Montalescot G; van 't Hof AW; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Collet JP; Goodman SG; Hammett CJ; Huber K; Janzon M; Lapostolle F; Lassen JF; Licour M; Merkely B; Salhi N; Silvain J; Storey RF; Ten Berg JM; Tsatsaris A; Zeymer U; Vicaut E; Hamm CW;
    JACC Cardiovasc Interv; 2016 Apr; 9(7):646-56. PubMed ID: 26952907
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prehospital Prasugrel Versus Ticagrelor in Real-World Patients With ST-Elevation Myocardial Infarction Referred for Primary PCI: Procedural and 30-Day Outcomes.
    Vos NS; Amoroso G; Vink MA; Maarse M; Adams R; Herrman JR; Patterson MS; van der Schaaf RJ; Slagboom T; de Winter RJ
    J Invasive Cardiol; 2018 Dec; 30(12):431-436. PubMed ID: 30318484
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
    Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
    Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
    Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
    Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Angiographic and electrocardiographic parameters of myocardial reperfusion in angioplasty of patients with ST elevation acute myocardial infarction loaded with ticagrelor or clopidogrel (MICAMI-TICLO trial).
    Winter JL; Lindefjeld DS; Veas N; Guarda E; Valdebenito M; Méndez M; Pérez O; Zuanic K; Mestas M; Martínez A
    Cardiovasc Revasc Med; 2014; 15(5):284-8. PubMed ID: 25178668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.